研究领域/方向

临床医学、肿瘤学（报考学科代码100214）：

1. 新型PROTAC靶向蛋白降解药物研发

2. 肿瘤代谢及肿瘤免疫

教育及工作经历

2023.4-至今，西安交通大学第一附属医院，青年拔尖人才（A类），教授

2018-2023，美国哈佛大学医学院贝斯以色列女执事医疗中心，博士后

2017-2018，西安交通大学，生命学院，讲师

2014-2016，美国哈佛医学院，肿瘤学，联合培养博士生

2010-2016，西安交通大学，生命学院，生物学，博士

2006-2010，西安交通大学，生命科学人才基地班，生物医学工程，本科

学术及科研成果

    长期致力于肿瘤及蛋白质翻译后修饰相关研究，针对肿瘤靶向治疗及免疫治疗开展了系统性工作，以第一/通讯作者在Science Advances（ESI高被引），Nature Communications（2篇），Cell Research（3篇），Journal of the American Chemical Society（4篇），Trends in Cell Biology及Seminar in Cancer Biology（2篇）等杂志发表论文16篇，他引2000余次，H因子29。研究成果被Nature Review Cancer，Nature Review Drug Discovery及Trends in Cell Biology等引用。

代表性论文

(*共同第一作者, ^#通讯作者)

1. J Wang*, Z Wang*, H Inuzuka, W Wei, J Liu^#. PRMT1 methylates METTL14 to modulate its oncogenic function. Neoplasia, 2023, 42, 100912
2. Liu J*, Bu, X*, Chu, C. Dai X, Asara J. et al. PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity. Nature Communications. 2023, 14, 2806.
3. Wang Z*, Liu J*, Chen H, Qiu X, Xie L, et al. Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins, Journal of the American Chemical Society. 2023, 17;145(19):10872-10879.
4. Liu J*, Yu X*, Chen H, Kaniskan H, Xie L, et al. TF-DUBTACs stabilize tumor suppressor transcription factors. Journal of the American Chemical Society. 2022, 144 (28), 12934-12941.
5. Liu J*, Peng Y*, Wei W^#. Cell cycle on the crossroad of tumorigenesis and cancer therapy. Trends in Cell Biology. 2022, 32(1): 30-44.
6. Liu J*, Peng Y*, Inuzuka H, Wei W^#. Targeting micro-environmental pathways by PROTACs as a therapeutic strategy. Seminars in Cancer Biology. 2022, 86(2): 269-279.
7. Liu J*, Peng Y*, Shi L*, Wan L, Inuzuka H, et al. Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle. Cell Research. 2021, 31(1): 80-93.
8. Liu J*, Tokheim C*, Lee JD, Gan W, North BJ, et al. Genetic fusions favor tumorigenesis through degron loss in oncogenes. Nature Communications. 2021, 12(1): 6704.
9. Liu J*, Chen H*, Kaniskan H, Xie L, Chen X, et al. TF-PROTACs enable targeted degradation of transcription factors. Journal of the American Chemical Society. 2021, 143(23): 8902-8910.
10. Liu J*, Chen H*, Liu Y, Shen Y, Meng F, et al. Cancer selective target degradation by folate-caged PROTACs. Journal of the American Chemical Society. 2021, 143(19): 7380-7387.
11. Liu J*, Ma J *, Liu Y *, Xia J, Li Y, et al. PROTACs: A novel strategy for cancer therapy. Seminars in Cancer Biology. 2020,  67, 171-179.
12. Liu J*, Chen H*, Ma L, He Z, Wang D, et al. Light-induced control of protein destruction by opto-PROTAC. Science advances. 2020, 6 (8), eaay5154

联系方式

电子邮箱：jingliu@xjtu.edu.cn